A Phase 1 TP-271 Oral PK Single Ascending Dose Study
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TP-271 in Healthy Adult Subjects, Including 1 Cross-over Arm
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
A PHASE1 clinical study on Bacterial Infections, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 10 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Jan 2021 — Jan 2022 [monthly]
Unknown Status PHASE1
▶ Show 5 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Oct 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE1
Status: Not Yet Recruiting → Active Not Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
- Tetraphase Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .